Strategic patent benchmark actions against Tuberculosis
DOI:
https://doi.org/10.34119/bjhrv6n2-279Keywords:
intellectual property, patent protection, neglected diseases, public policies, tb burdenAbstract
Tuberculosis (TB) is the second cause of death lead by infectious disease worldwide and with a growing incidence and death rates by 2022. United Nations preventive and treatment targets to fight TB were unmet and the upcoming TB patent portfolio is vulnerable what jeopardize global progress against TB. Funding for TB research is limited and strategical initiatives through intellectual property could be applied to optimize public and private efforts to fight TB epidemic. To stimulate the research and drug market aspects related with TB technologies, it was synthetized through searches in technological databases 15 strategic actions to enhance development and access of TB assets at regional, national and international level.
References
World Health Organization. Global Tuberculosis Report 2021. WHO, Geneva, 2021. https://www.who.int/publications/i/item/9789240037021
World Health Organization. Global Tuberculosis Report 2022. WHO, Geneva, 2022. https://www.who.int/publications/i/item/9789240061729
Rogério Almeida Meneghin; Ana Elenonora Paixão. Elementos para elaboração de políticas públicas de patentes dedicadas à tuberculose. 1. ed. Curitiba Paraná: Appris Editora, 2019. v. 1. 471p. ISBN: 978-85-473-3204-4. Data de publicação: 11 de dezembro de 2019. Disponível em: https://editoraappris.com.br/produto/elementos-para-elaboracao-de-politicas-publicas-de-patentes-dedicadas-a-tuberculose/
Silva, J. L. R. da, Andrade, K. de J., Otéro, R. da C., Sousa, K. E. P. de, Brito, M. A., & Almeida, A. C. G. de. (2022). Aspectos relacionados à eficácia do tratamento da tuberculose: revisão sistemática: Aspects related to the effectiveness of tuberculosis treatment: a systematic review. Brazilian Journal of Health Review, 5(6), 25221–25237. https://doi.org/10.34119/bjhrv5n6-261
Silva, T. M. da, Victório, M. A., Nunes, P. L. P., & Paula, M. M. M. de. (2021). Estudo retrospectivo da Tuberculose no período de 2014 a 2019 / Retrospective study of Tuberculosis in the period from 2014 to 2019. Brazilian Journal of Health Review, 4(3), 14195–14210. https://doi.org/10.34119/bjhrv4n3-352
Coherent Market Insights. Global Tuberculosis Drugs Market, By Therapy Type (First Line Drugs Therapy, Second Line Drugs Therapy, Combination Drugs Therapy), and Geography: global industry insights, trends, outlook, and opportunity analysis, 2016-2024. Seattle: Coherent Market Insights, 2017. 139 p. Report code: CMI6191. https://www.coherentmarketinsights.com/market-insight/tuberculosis-drugs-market-191
Rede de Valor para Inteligência Empresarial. Prospecção de inteligência de mercado e de produtos sobre tuberculose. São Paulo: REVIE, 2017.
Brazil. Lei Federal Nº 9.279, de 14 de maio de 1996. Regula direitos e obrigações relativos à propriedade industrial. Diário Oficial da União, Brasilia, 1996. https://www.planalto.gov.br/ccivil_03/leis/l9279.htm
Instituto Nacional de Propriedade Intelectual. Resolução INPI/PR Nº 237, de 28 de março de 2019. Institui o Projeto-piloto Prioridade BR IV. Rio de Janeiro: INPI, 2019.
J.P. Love. Recent examples of the use of compulsory licenses on patents. KEI Research Note 2. Knowledge Ecology International, Washington DC, 2007. https://www.keionline.org/misc-docs/recent_cls_8mar07.pdf
Scopel CT, Chaves GC. Iniciativas de enfrentamento da barreira patentária e a relação com o preço de medicamentos adquiridos pelo Sistema Único de Saúde. Cad. Saúde Pública, 32 (2016), pp. e00113815.https://www.scielo.br/j/csp/a/gFLfqN5VLSjqChf784XMdwv/?lang=pt
A.B. Mehl. The Hatch-Waxman Act and market exclusivity for generic drug manufactures: an entitlement or an incentive? Chi.-Kent L. Rev., 81 (2006), pp. 649-677. https://scholarship.kentlaw.iit.edu/cgi/viewcontent.cgi?article=3541&context=cklawreview
For more see: http://www.gavi.org/
Moir, Hazel V. J., Pharmaceutical Patents and Evergreening (March 31, 2021). Available at SSRN: https://ssrn.com/abstract=3975947 or http://dx.doi.org/10.2139/ssrn.3975947
For more see https://medicineslawandpolicy.org/
For more see https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2023
El Said, M.. The Impact of ‘TRIPS-Plus’ Rules on the Use of TRIPS Flexibilities: Dealing with the Implementation Challenges. In: Correa, C.M., Hilty, R.M. (eds) Access to Medicines and Vaccines (2022). Springer, Cham. https://doi.org/10.1007/978-3-030-83114-1_11
For more see https://medicinespatentpool.org/
For more see https://accessibsa.org/
For more see https://www.wipo.int/pat-informed/en/
For more see https://www.citizen.org/article/kaletra-campaign/
For more see https://www.theglobalfund.org/en/tuberculosis/
